Tofacitinib and Abatacept: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 16, 2026 · Source data updated Jul 16, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Tofacitinib
Abatacept
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Tofacitinib (Xeljanz) and abatacept (Orencia) both calm down your immune system. They work in different ways, but the concern is the same: when you take them together, your body may have a harder time fighting off germs. That means a higher chance of catching an infection, sometimes a serious one.
Because of this, doctors generally do not recommend using these two medicines at the same time. This advice is based more on caution than on hard proof, since we simply don't have enough safety data on the combination. The good news is that your care team can help you find a safer plan. Please don't stop either drug on your own, just talk with your pharmacist or doctor about the best option for you.
Effect: Additive immunosuppression and increased infection risk when tofacitinib (a JAK inhibitor) is combined with abatacept (a selective T-cell costimulation modulator).
- Mechanism: Unknown/unspecified; presumed additive immunomodulatory effect (PD interaction). Neither agent's metabolism drives this. No prodrug consideration applies.
- Direction/magnitude: Increased net immunosuppression; magnitude not quantified.
- Evidence: Theoretical; insufficient safety/efficacy data for concurrent biologic-plus-JAK-inhibitor use.
- Onset: Unspecified.
- Management: Concurrent use is not recommended. If a patient is exposed to both, monitor closely for signs of infection and coordinate a single targeted immunomodulatory regimen.
What happens
An increased risk of infection
Interaction Deep Dive
Adequate data are not available to assess whether abatacept can be used safely and effectively alongside janus kinase inhibitors. As a result, using these medications together is advised against1.
Why it happens (mechanism)
Unknown
How to manage this interaction
The general recommendation is that these two are not used together because combining them can raise your infection risk without added benefit.
- Keep taking your medications as prescribed. Do not start, stop, or change either one on your own.
- Tell your prescriber and pharmacist about every immune medicine you take so they can pick one targeted therapy rather than both.
- Watch for signs of infection such as fever, chills, cough, sore throat, burning with urination, or a wound that won't heal, and report them promptly.
- If both are ever prescribed, your care team may monitor you more closely.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Tofacitinib and Abatacept together?
Tofacitinib and abatacept both suppress the immune system, so using them together is generally not recommended due to a higher infection risk. Don't stop either one yourself; ask your doctor or pharmacist which single therapy is right for you. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Tofacitinib and Abatacept interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Tofacitinib and Abatacept interaction managed?
The general recommendation is that these two are not used together because combining them can raise your infection risk without added benefit. Keep taking your medications as prescribed. Do not start, stop, or change either one on your own. Tell your prescriber and pharmacist about every immune medicine you take so they can pick one targeted therapy rather than both. Watch for signs of infection s… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Tofacitinib or Abatacept need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: ORENCIA(R) intravenous, subcutaneous injection, abatacept intravenous, subcutaneous injection. Bristol-Myers Squibb Company (per FDA), Princeton, NJ, 2020. DailyMed
Keep reading about Tofacitinib
Keep reading about Abatacept
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist